Novel and stable compstatin analogues

A compound of formula (Ia),

• (Ia)
• (SEQ ID NO:
• 117)
• Y2-Z2-X0-X1-X2-X3-X4-X5-X6-X7-X8-X9-
• X10-X11-X12-X13-Z1-Y1
• or salt thereof, wherein
• X0 is DTyr,
• X1 is I,
• X2 is C,
• X3 is Tle,
• X4 is TrpMe,
• X5 is bhAsn or DprAc,
• X6 is D,
• X7 is W,
• X8 is Sar,
• X9 is A or E,
• X10 is H,
• X11 is R,
• X12 is PEN,
• X13 is selected from the group consisting of DArg, DLys, DThr, DPhe, P, and NMeF,
• wherein the compound has a disulphide bridge between the sulphur atoms of X2 and X12,
• and wherein
• (a) Z1 is a sequence of n amino acid residues independently selected from a group consisting of K, E, and gGlu, DLys and DgGlu, n is an integer selected from 1 to 4, Y1 is OH, Z2 is absent, and Y2 is hydrogen;
• or
• (b) Z1 is absent, Y1 is selected from the group consisting of OH, K—OH, and NH2, Z2 is a sequence of m amino acid residues independently selected from a group consisting of K, E, and gGlu, m is an integer selected from 1 to 4, and Y2 is hydrogen (SEQ ID NO:
• 118);
• wherein
• Tle refers to the residue of L-tert-butylglycine,
• TrpMe refers to the residue of 1-methyl-L-tryptophan,
• bhAsn refers to the residue of beta-homo-L-asparagine,
• DprAc refers to the residue of (2S)-2-amino-3-acetamidopropanoic acid,
• Sar refers to the residue of sarcosine,
• PEN refers to the residue of L-penicillamine,
• NMeI refers to the residue of N-methyl-L-isoleucine,
• NMeF refers to the residue of N-methyl-L-phenylalanine,
• APCA refers to the residue of 4-amino-piperidine-4 carboxylic acid, and
• gGlu refers to the residue of gamma-L-glutamate.